Gevokizumab: Phase III data

The double-blind, European Phase III EYEGUARD-B trial in 83 patients with Behcet’s uveitis showed that once-monthly 60 mg subcutaneous gevokizumab plus standard of care (SOC) consisting of immunosuppr...